Literature DB >> 2119630

In vivo release of dopa and dopamine from genetically engineered cells grafted to the denervated rat striatum.

P Horellou1, P Brundin, P Kalén, J Mallet, A Björklund.   

Abstract

Fibroblastic 3T3 and endocrine RIN cells were genetically modified by infection with a recombinant retrovirus encoding the form I of human tyrosine hydroxylase (TH) and selection in tyrosine-free medium. These cells were grafted to rats unilaterally lesioned with 6-hydroxy-dopamine. Both cell types survived implantation into the striatum, expressed TH immunoreactivity, and as assessed by microdialysis 8-9 days after implantation, secreted high amounts of DOPA and/or dopamine into the surrounding host striatum. The modified 3T3 cells secreted large amounts of DOPA that was efficiently decarboxylated to dopamine by the host striatal tissue; the newly synthesized dopamine was stored only to a limited extent in the denervated striatum. The modified RIN cells synthesized dopamine that was stored intracellularly and released in a regulated fashion. The grafted DOPA-secreting cells produced 4-5 times higher extracellular dopamine levels than the dopamine-secreting cells, and they were more efficient in reducing apomorphine-induced rotation. No effect was observed with either cell type on amphetamine-induced turning behavior.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2119630     DOI: 10.1016/0896-6273(90)90078-t

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  19 in total

1.  Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer.

Authors:  Deniz Kirik; Biljana Georgievska; Corinna Burger; Christian Winkler; Nicholas Muzyczka; Ronald J Mandel; Anders Bjorklund
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-26       Impact factor: 11.205

Review 2.  Gene therapy in clinical medicine.

Authors:  S M Selkirk
Journal:  Postgrad Med J       Date:  2004-10       Impact factor: 2.401

3.  Double transduction with GTP cyclohydrolase I and tyrosine hydroxylase is necessary for spontaneous synthesis of L-DOPA by primary fibroblasts.

Authors:  C Bencsics; S R Wachtel; S Milstien; K Hatakeyama; J B Becker; U J Kang
Journal:  J Neurosci       Date:  1996-07-15       Impact factor: 6.167

4.  Neurotrophic factors in neurodegenerative disorders: model of Parkinson's disease.

Authors:  J Garcia de Yebenes; J Yebenes; M A Mena
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

Review 5.  Gene therapy for Parkinson's disease.

Authors:  P Horellou; J Mallet
Journal:  Mol Neurobiol       Date:  1997-10       Impact factor: 5.590

Review 6.  Maintaining the neuronal phenotype after injury in the adult CNS. Neurotrophic factors, axonal growth substrates, and gene therapy.

Authors:  M H Tuszynski; F H Gage
Journal:  Mol Neurobiol       Date:  1995 Apr-Jun       Impact factor: 5.590

7.  Pharmacologic characterization of opioid peptide release from chromaffin cell transplants using a brain slice superfusion method.

Authors:  J D Ortega; J Sagen
Journal:  Exp Brain Res       Date:  1993       Impact factor: 1.972

8.  Generation of tyrosine hydroxylase-producing neurons from precursors of the embryonic and adult forebrain.

Authors:  M M Daadi; S Weiss
Journal:  J Neurosci       Date:  1999-06-01       Impact factor: 6.167

Review 9.  Tyrosine hydroxylase and Parkinson's disease.

Authors:  J Haavik; K Toska
Journal:  Mol Neurobiol       Date:  1998-06       Impact factor: 5.590

Review 10.  Clinical application of neuronal grafts in Parkinson's disease.

Authors:  O Lindvall
Journal:  J Neurol       Date:  1994-12       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.